In 2015 was created Dementia Discovery Fund, which is appeared as VC. The main office of represented VC is situated in the London. The fund was located in Europe if to be more exact in United Kingdom.
The fund is generally included in 2-6 deals every year. The increased amount of exits for fund were in 2019. The real fund results show that this VC is 13 percentage points more often commits exit comparing to other companies. The top activity for fund was in 2018. Deals in the range of 10 - 50 millions dollars are the general things for fund. Opposing the other organizations, this Dementia Discovery Fund works on 12 percentage points less the average amount of lead investments.
Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. The fund has exact preference in some founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the most successful fund investment fields, there are Health Care, Life Science. Among the most popular portfolio startups of the fund, we may highlight Alector, MedaRed, Mitoconix Bio. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Dementia Discovery Fund, startups are often financed by SV Health Investors, Polaris Partners, OrbiMed. The meaningful sponsors for the fund in investment in the same round are AbbVie Biotech Ventures, Amgen Ventures, SV Health Investors. In the next rounds fund is usually obtained by Illumina Ventures, Amgen Ventures, AbbVie Biotech Ventures.
The overall number of key employees were 3.
Fund Name | Location |
AlphaX Partners | Beijing, Beijing, China |
Bridge Link Capital | England, London, United Kingdom |
Chengyu Touzi Youxian Gongsi | - |
Dolik Ventures | New York, New York, United States |
Grupo Logistico Andreani | - |
HP Capital | California, Culver City, United States |
Latitud | Brazil, São Paulo, Sao Paulo |
SP Acquisitions | New York, New York, United States |
United Education Company | Al Asimah, Al Kuwayt, Kuwait |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Montara Therapeutics | $8M | 30 Jul 2024 | San Francisco, California, United States | ||
AstronauTx | $65M | 08 Oct 2023 | United Kingdom, England, United Kingdom | ||
Violet Therapeutics | $10M | 05 May 2023 | Cambridge, Massachusetts, United States | ||
Therini Bio | $36M | 27 Apr 2023 | San Francisco, California, United States | ||
Cerevance | $51M | 13 Feb 2023 | Cambridge, Massachusetts, United States | ||
Amphista Therapeutics | 13 Dec 2022 | United Kingdom, Scotland, United Kingdom | |||
Transine Therapeutics | $6M | 31 May 2022 | Cambridge, England, United Kingdom | ||
AviadoBio | $80M | 02 Dec 2021 | London, England, United Kingdom | ||
LOQUS23 THERAPEUTICS | $9M | 23 Nov 2021 | London, England, United Kingdom |
– Alchemab Therapeutics from Cambridge, England, UK develops a platform that enables the identification of novel drug targets and therapeutics on the basis of patient B-cell antibody repertoires.
– The company raised £60m in Series A funding.
– The round was led by RA Capital Management, with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund.
– The new investment will be used to advance the company’s target-agnostic drug discovery platform.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Montara Therapeutics | $8M | 30 Jul 2024 | San Francisco, California, United States | ||
AstronauTx | $65M | 08 Oct 2023 | United Kingdom, England, United Kingdom | ||
Violet Therapeutics | $10M | 05 May 2023 | Cambridge, Massachusetts, United States | ||
Therini Bio | $36M | 27 Apr 2023 | San Francisco, California, United States | ||
Cerevance | $51M | 13 Feb 2023 | Cambridge, Massachusetts, United States | ||
Amphista Therapeutics | 13 Dec 2022 | United Kingdom, Scotland, United Kingdom | |||
Transine Therapeutics | $6M | 31 May 2022 | Cambridge, England, United Kingdom | ||
AviadoBio | $80M | 02 Dec 2021 | London, England, United Kingdom | ||
LOQUS23 THERAPEUTICS | $9M | 23 Nov 2021 | London, England, United Kingdom |